Mankind Pharma Q3FY26 Revenue Up 11.5% to ₹3,567 Crore; Adj. EBITDA Margin at 25.9%
Mankind Pharma reported Q3FY26 revenue of ₹3,567 Crore, up 11.5% YoY. Adjusted EBITDA margin was 25.9%. Domestic revenue grew 11.1% to ₹3,046 Crore. For 9M FY26, revenue rose 18.7% to ₹10,835 Crore. An earnings concall is scheduled for February 3, 2026.
The results show steady growth and improved operational efficiency, which are positive indicators for the company's performance.
The company reported revenue growth and improved margins, along with positive commentary on business drivers and future outlook.
Mankind Pharma announced its financial results for the third quarter and nine months ended December 31, 2025, reporting a consolidated revenue from operations of ₹3,567 Crore, an increase of 11.5% year-on-year (YoY). The domestic revenue grew by 11.1% YoY to ₹3,046 Crore, while exports saw a 14.1% YoY increase to ₹521 Crore.
The company reported an Adjusted EBITDA margin of 25.9% for Q3FY26, with a Profit After Tax (PAT) margin of 11.6%. Diluted Earnings Per Share (EPS) stood at ₹9.9, a 6.7% increase YoY.
For the nine months ended December 31, 2025 (9M FY26), revenue from operations reached ₹10,835 Crore, up 18.7% YoY. The Adjusted EBITDA margin for the period was 24.9%, and the PAT margin was 12.7%. Diluted EPS for 9M FY26 was ₹32.9, a decrease of 15.4% YoY.
Mr. Rajeev Juneja, Vice Chairman & Managing Director, highlighted that the revenue growth was primarily driven by improvements in the domestic pharma business and BSV consolidation. The company's chronic share increased by 200 basis points YoY to 39.3%, fueled by strong growth in cardiac (16.7%) and anti-diabetic (14.4%) segments. The Consumer Healthcare business regained sequential growth momentum with a 5.2% YoY revenue increase in Q3FY26.
Mankind Pharma will host an earnings concall on February 3, 2026, from 06:00 pm to 07:00 pm IST to discuss the results.
What to do with a filing like this
Mankind Pharma Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Mankind Pharma Limited. Read the original for the full detail.